RESUMEN
ACuteTox is a project within the 6th European Framework Programme which had as one of its goals to develop, optimise and prevalidate a non-animal testing strategy for predicting human acute oral toxicity. In its last 6 months, a challenging exercise was conducted to assess the predictive capacity of the developed testing strategies and final identification of the most promising ones. Thirty-two chemicals were tested blind in the battery of in vitro and in silico methods selected during the first phase of the project. This paper describes the classification approaches studied: single step procedures and two step tiered testing strategies. In summary, four in vitro testing strategies were proposed as best performing in terms of predictive capacity with respect to the European acute oral toxicity classification. In addition, a heuristic testing strategy is suggested that combines the prediction results gained from the neutral red uptake assay performed in 3T3 cells, with information on neurotoxicity alerts identified by the primary rat brain aggregates test method. Octanol-water partition coefficients and in silico prediction of intestinal absorption and blood-brain barrier passage are also considered. This approach allows to reduce the number of chemicals wrongly predicted as not classified (LD50>2000 mg/kg b.w.).
Asunto(s)
Redes Neurales de la Computación , Pruebas de Toxicidad Aguda , Administración Oral , Alternativas a las Pruebas en Animales , Animales , Barrera Hematoencefálica/metabolismo , Línea Celular , Supervivencia Celular , Ensayo de Unidades Formadoras de Colonias , Simulación por Computador , Citocinas/metabolismo , Humanos , Absorción Intestinal , Dosificación Letal Mediana , Ratones , Estrés Oxidativo , Ratas , Medición de RiesgoRESUMEN
A neural model based on a numerical molecular representation using CODES program to predict oral absorption of any structure is described. This model predicts both high and low-absorbed compounds with a global accuracy level of 74%. CODES/ANN methodology shows promising utilities not only as a conventional in silico tool in high-throughput screening or improvement of absorption capabilities procedures but also the improvement of in vitro-in vivo correlation could be addressed.
Asunto(s)
Modelos Químicos , Tecnología Farmacéutica , Administración Oral , Humanos , Redes Neurales de la Computación , Permeabilidad , Relación Estructura-Actividad CuantitativaRESUMEN
Chagas disease, also known as American trypanosomiasis, is caused by infection with the protozoan parasite Trypanosoma cruzi. The Pan American Health Organization (PAHO) estimates that currently 7.7 million of people have Trypanosoma cruzi infection in the 21 endemic countries from the southern and southwestern United States to central Argentina and Chile. The only approved therapeutics for the treatment of Chagas disease are two nitroheterocyclic compounds as a nitrofuran (nifurtimox; Lampit) and a nitroimidazole (benznidazole; Rochagan). However, the anti-Trypanosoma cruzi activities of these compounds were discovered empirically over three decades ago. The treatment of Chagas disease with nifurtimox or benznidazole is unsatisfactory because of their limited efficacy in the prevalent chronic stage of the disease and their toxic side effects. In this context, this article will review the current knowledge of the different aspects involved in this illness, such as Trypanosoma cruzi transmission, physiology and biochemistry of the etiological agent, epidemiological aspects and current treatments for American trypanosomiasis. An important section of this review will focus on the different strategies in drug discovery for Chagas disease, including methodology, in vitro screening studies against whole parasites, novel rationally developed approaches on the basis of the increasing knowledge of the biochemistry of Trypanosoma cruzi and the recent progress in the understanding and validation of several targets for the therapy of Chagas's disease. A summary of the most relevant drug targets such as sterol biosynthesis pathway, cysteine protease pathway, pyrophosphate metabolism and purine salvage pathway will be reviewed. Moreover, recent studies regarding other strategies currently under development including thiol-dependent redox metabolism, lysophospholipid analogues and DNA binders will also be discussed.
Asunto(s)
Enfermedad de Chagas/etiología , Trypanosoma cruzi/efectos de los fármacos , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/epidemiología , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/uso terapéutico , Ergosterol/biosíntesis , Ergosterol/metabolismo , Glutatión/análogos & derivados , Glutatión/química , Glutatión/uso terapéutico , Humanos , Hipoxantina Fosforribosiltransferasa/metabolismo , Espermidina/análogos & derivados , Espermidina/química , Espermidina/uso terapéuticoRESUMEN
Alzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer's disease.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Moduladores de Receptores de Cannabinoides/metabolismo , Cannabinoides/metabolismo , Receptores de Cannabinoides/metabolismo , Enfermedad de Alzheimer/terapia , Animales , Transporte Biológico , Moduladores de Receptores de Cannabinoides/biosíntesis , Humanos , LigandosRESUMEN
The synthesis, pharmacological evaluation, and structure-activity relationships of a new class of bronchodilator agents, derivatives of pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides are described. The compounds were prepared by reaction of 3,4,5-triamino-1,2, 6-thiadiazine 1,1-dioxide with suitable 1,2-dicarbonyl compounds or alpha-hydroxyiminoketones and subsequent N-alkylation. A transamination procedure for synthesizing derivatives with different substituents at the 4-amino group is reported for the first time. The pyrazino[2,3-c][1,2,6]thiadiazine derivatives were screened for tracheal relaxing activity in vitro, and the active compounds were evaluated in vivo in guinea pigs as bronchodilator agents in comparison to theophylline. Among the compounds studied, the most interesting properties were displayed by the 4-amino-1-ethyl-6-methyl derivative (21). The toxicological evaluation of this derivative is also reported.
Asunto(s)
Broncodilatadores/síntesis química , Pirazinas/síntesis química , Tiadiazinas/síntesis química , Animales , Broncoconstricción/efectos de los fármacos , Broncodilatadores/química , Broncodilatadores/farmacología , Cobayas , Dosificación Letal Mediana , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Relajación Muscular , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Pirazinas/química , Pirazinas/farmacología , Ratas , Relación Estructura-Actividad , Tiadiazinas/química , Tiadiazinas/farmacología , Pruebas de Toxicidad Aguda , Tráquea/efectos de los fármacos , Tráquea/fisiologíaRESUMEN
In the previous paper (Part 1), we described the synthesis and antiplatelet activity of a series of phenyl- and heteroarylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. In this paper, we report the optimization of the platelet aggregation inhibitory activity by an iterative sequence of quantitative structure-activity relationship studies which encompassed synthesis and evaluation of the effects of structure variations at the 1-, 6-, and 7-positions of the heterocyclic system. A model has been established that correctly correlates antiplatelet activity in this series with the partial atomic charges calculated by a local density functional ab initio method. As a result of this study, the experimental platelet aggregation inhibitory activity of the lead compound was improved 300-fold.
Asunto(s)
Inhibidores de Agregación Plaquetaria/química , Tiadiazinas/química , Animales , Técnicas In Vitro , Modelos Moleculares , Inhibidores de Agregación Plaquetaria/síntesis química , Inhibidores de Agregación Plaquetaria/farmacología , Conejos , Relación Estructura-Actividad , Tiadiazinas/síntesis química , Tiadiazinas/farmacologíaRESUMEN
A series of N-1-substituted derivatives of pyrazino[2,3-c][1,2, 6]thiadiazine 2,2-dioxides bearing aryl groups at the pyrazino moiety have been prepared. The synthesis involves ring formation between the diaminothiadiazine and suitable dicarbonyl compounds and subsequent introduction of the substituent at N-1. The compounds have been tested in vitro, as inhibitors of rabbit and human platelet aggregation, and ex vivo against rat platelet aggregation induced by arachidonic acid, ADP, collagen, U46619, and I-BOP. The results obtained indicate that some pyrazino[2,3-c][1,2, 6]thiadiazine derivatives show significant platelet aggregation inhibition similar to other antithrombotic agents and that the antiplatelet properties may be mediated by interference with the arachidonic acid pathway.
Asunto(s)
Óxidos S-Cíclicos/síntesis química , Inhibidores de Agregación Plaquetaria/síntesis química , Tiadiazinas/síntesis química , Animales , Óxidos S-Cíclicos/química , Óxidos S-Cíclicos/farmacología , Humanos , Técnicas In Vitro , Masculino , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/farmacología , Conejos , Ratas , Ratas Wistar , Relación Estructura-Actividad , Tiadiazinas/química , Tiadiazinas/farmacologíaRESUMEN
Different aspects of a particular kind of heterocycle, namely pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide are discussed. These include synthesis, reactivity, tautomerism and acid-base properties, results of x-ray analysis and molecular orbital calcultations. Besides, some of the derivatives have shown interesting biological effects, among which are the diuretic properties which are also presented.
Asunto(s)
Diuréticos/síntesis química , Pirazinas/síntesis química , Tiadiazinas/síntesis química , Animales , Diuréticos/farmacología , Pirazinas/farmacología , Ratas , Tiadiazinas/farmacologíaRESUMEN
The synthesis and evaluation of a new class of diuretic agents derived from the pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide ring system are described. Preliminary structure-activity relationships indicate that the nature and location of the substituents at different positions of the heterocycle are crucial for activity. Thus, a novel synthetic methodology has been developed to selectively introduce the desired substituents at different positions. From the study of the pharmacological properties (dose-response curves, duration of action, and acute toxicity) of the most active compounds, 4-amino-1,7-diethyl-6-methylpyrazino[2,3-c][1,2,6]thiadiazine++ + 2,2-dioxide (9) was selected for further investigation. Compound 9 (C10H15N5O2S) crystallizes in space group P21/a with unit cell dimensions a = 16.482 (1), b = 9.3484 (3), c = 8.333 (3) A, beta = 103.003 (3) degrees, Z = 4.
Asunto(s)
Diuréticos/síntesis química , Tiadiazinas/síntesis química , Animales , Diuréticos/farmacología , Masculino , Ratones , Modelos Moleculares , Estructura Molecular , Natriuresis/efectos de los fármacos , Pirazinas/síntesis química , Pirazinas/farmacología , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Tiadiazinas/farmacología , Difracción de Rayos XRESUMEN
The synthesis of new 3,5-diamino-1,2,6-thiadiazine 1,1-dioxide derivatives is described and their structures discussed on the basis of 1H and 13C-N.M.R. data. The antiparasitic activity of these and related compounds was evaluated. The bacterial mutagenicity of the parent compound (I) was studied.